Trial · NCT04832100
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 20
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Questionnaire: Numeric rating scale (NRS) for pain and soreness | Changes from baseline NRS at 2 weeks are assessed | assessment of pain and soreness severity. Score: 0(no symptom) \~10 (worst symptom) |
| Primary | Questionnaire: Numeric rating scale (NRS) for pain and soreness | Changes from baseline NRS at 4 weeks are assessed | assessment of pain and soreness severity. Score: 0(no symptom) \~10 (worst symptom) |
| Primary | Questionnaire: widespread pain index and widespread soreness index | Change from baseline widespread index at 2 weeks are assessed | assessment of pain and soreness diffuseness. Score: 0(no symptom) \~19 (mostly diffused symptom) |
| Primary | Questionnaire: widespread pain index and widespread soreness index | Change from baseline widespread index at 4 weeks are assessed | assessment of pain and soreness diffuseness. Score: 0(no symptom) \~19 (mostly diffused symptom) |
| Primary | Questionnaire: Fibromyalgia impact questionnaire (FIQR) | Change from baseline FIQR at 2 weeks are assessed | assessment of fibromyalgia impacts and disease severity. Score: 0(no symptom) \~100 (worst symptom) |
| Primary | Questionnaire: Fibromyalgia impact questionnaire (FIQR) | Change from baseline FIQR at 4 weeks are assessed | assessment of fibromyalgia impacts and disease severity. Score: 0(no symptom) \~100 (worst symptom) |
| Primary | Questionnaire: Hospital Anxiety and Depression Scale (HADS) | Change from baseline HADS at 2 weeks are assessed | assessment of psychological distress. Score: 0 (no symptom) \~42 (worst symptom) |
| Primary | Questionnaire: Hospital Anxiety and Depression Scale (HADS) | Change from baseline HADS at 4 weeks are assessed | assessment of psychological distress. Score: 0 (no symptom) \~42 (worst symptom) |
| Primary | Questionnaire: The Pittsburgh Sleep Quality Index (PSQI) | Change from baseline PSQI at 2 weeks are assessed | assessment of sleep quality. Score: 0 (no symptom) \~21 (worst sleep quality) |
| Primary | Questionnaire: The Pittsburgh Sleep Quality Index (PSQI) | Change from baseline PSQI at 4 weeks are assessed | assessment of sleep quality. Score: 0 (no symptom) \~21 (worst sleep quality) |
| Primary | Questionnaire: Perceived stress scale (PSS) | Change from baseline PSS at 2 weeks are assessed | assessment of perceived stress loading. Score: 0 (no stress) \~40 (highest stressed level) |
| Primary | Questionnaire: Perceived stress scale (PSS) | Change from baseline PSS at 4 weeks are assessed | assessment of perceived stress loading. Score: 0 (no stress) \~40 (highest stressed level) |
| Primary | Metabolomics investigation | Change from baseline metabolomics at 3 months are assessed | Laboratory investigation of metabolomic expression, including lactate, creatine, malondialdehyde, protein carbonyls and amino acids. |
| Primary | Lipidomics investigation | Change from baseline metabolomics at 3 months are assessed | Laboratory investigation of lipidomic expression, including phosphocholine, sphingomyelin, lysophosphatidylcholine and ceramide. |
| Primary | Metabolomics investigation | Change from baseline metabolomics at 6 months are assessed | Laboratory investigation of metabolomic expression, including lactate, creatine, malondialdehyde, protein carbonyls and amino acids. |
| Primary | Lipidomics investigation | Change from baseline metabolomics at 6 months are assessed | Laboratory investigation of lipidomic expression, including phosphocholine, sphingomyelin, lysophosphatidylcholine and ceramide. |
| Primary | Metabolomics investigation | Change from baseline metabolomics at 9 months are assessed | Laboratory investigation of metabolomic expression, including lactate, creatine, malondialdehyde, protein carbonyls and amino acids. |
| Primary | Lipidomics investigation | Change from baseline metabolomics at 9 months are assessed | Laboratory investigation of lipidomic expression, including phosphocholine, sphingomyelin, lysophosphatidylcholine and ceramide. |
| Primary | Metabolomics investigation | Change from baseline metabolomics at 12 months are assessed | Laboratory investigation of metabolomic expression, including lactate, creatine, malondialdehyde, protein carbonyls and amino acids. |
| Primary | Lipidomics investigation | Change from baseline metabolomics at 12 months are assessed | Laboratory investigation of lipidomic expression, including phosphocholine, sphingomyelin, lysophosphatidylcholine and ceramide. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04832100/registered